Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: Diminishing treatment-related morbidity while maintaining efficacy

Annals of Oncology

Volumn 21, Issue 6, 2009, Pages 1296-1301

  Kollmannsberger, C ^a   Moore, C ^b   Chi, K N ^a   Murray, N ^a   Daneshmand, S ^c   Gleave, M ^d   Hayes Lattin, B ^e   Nichols, C R ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Providence Cancer Center   (Canada)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Nonseminomatous testicular cancer; Stage I; Surveillance; Testis cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TESTIS CANCER; ADJUVANT CHEMOTHERAPY; COMORBIDITY; EVALUATION STUDY; HEALTH SURVEY; MIDDLE AGED; MORTALITY; NEOPLASMS, GERM CELL AND EMBRYONAL; POSTOPERATIVE COMPLICATIONS; PROCEDURES; RECURRENT DISEASE; RISK; STATISTICS AND NUMERICAL DATA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; POPULATION SURVEILLANCE; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; RISK; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950592867     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp473     Document Type: Article

References (30)

1. Sonneveld DJ, Hoekstra HJ, Van Der Graaf WT et al. The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. BJU Int 1999; 84: 68-74.
2. Powles TB, Bhardwa J, Shamash J et al. The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int 2005; 95: 1197-1200.
3. Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992; 10: 1762-1768.
4. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007; 64: 182-197.
5. Vergouwe Y, Steyerberg EW, Eijkemans MJ et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 2003; 21: 4092-4099.
6. Pizzocaro G, Zanoni F, Salvioni R et al. Surveillance or lymph node dissection in clinical stage I non-seminomatous germinal testis cancer? Br J Urol 1985; 57: 759-762.
7. Peckham MJ, Brada M. Surveillance following orchidectomy for stage I testicular cancer. Int J Androl 1987; 10: 247-254.
8. Klepp O, Olsson AM, Henrikson H et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 1990; 8: 509-518.
9. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53: 497-513.
10. Mead G. Group ftIGCCC. International Germ Cell Collaborative Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
11. Oliver RT, Ong J, Shamash J et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004; 63: 556-561.
12. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 2003; 111: 76-83.
13. Colls BM, Harvey VJ, Skelton L et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 1999; 83: 76-82.
14. Tandstad T, Dahl O, Cohn-Cedermark G et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122-2128.
15. Francis R, Bower M, Brunstrom G et al. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 2000; 36: 1925-1932.
16. Duran I, Sturgeon JF, Jewett MA et al. Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). J Clin Oncol 2007; 25(18S): (Abstr 5021).
17. Maroto P, Garcia del Muro X, Aparicio J et al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol 2005; 16: 1915-1920.
18. Albers P, Siener R, Krege S et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26: 2966-2972.
19. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-1732.
20. Fossa SD, Lehne G, Heimdal K, Theodorsen L. Clinical and biochemical longterm toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 1995; 52: 300-305.
21. Fossa SD, Aass N, Winderen M et al. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 2002; 13: 222-228.
22. Haugnes HS, AassN, Fossa SD et al. Components of the metabolic syndrome inlongterm survivors of testicular cancer. Ann Oncol 2007; 18: 241-248.
23. Hao D, Seidel J, Brant R et al. Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol 1998; 160: 768-771.
24. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-2284.
25. Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 2009; 181: 627-632.
26. Tubiana M, Aurengo A, Averbeck D, Masse R. The debate on the use of linear no threshold for assessing the effects of low doses. J Radiol Prot 2006; 26: 317-324.
27. Tubiana M, Aurengo A, Averbeck D, Masse R. Recent reports on the effect of low doses of ionizing radiation and its dose-effect relationship. Radiat Environ Biophys 2006; 44: 245-251.
28. Aurengo A, Averbeck D, Bonnin A et al. Dose-Effect Relationships and the Estimation of the Carcinogenic Effects of Low Doses of Ionizing Radiation. Paris, France: National Academy of Medicine 2005 http://www.radscihealth.org/rsh/Papers/FrenchAcadsFinal2007_2004_2005.pdf (20 May 2009, date last accessed).
29. Tubiana M. Computed tomography and radiation exposure. N Engl J Med 2008; 358: 850 author reply 852-853.
30. Rustin GJ, Mead GM, Stenning SP et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007; 25: 1310-1315.